

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A therapeutic agent for a hormone-dependent cancer, which comprises:

(a) a steroid-sulfatase inhibitor; and

(b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval.

Claim 2 (currently amended): A method for treating a hormone-dependent cancer, which comprises:

administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval.

Claim 3 (currently amended): A steroid-sulfatase inhibitor, which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval.

Claim 4 (currently amended): A kit for treating a hormone-dependent cancer, which comprises:

a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy.


Claim 5 (currently amended): A pharmaceutical composition, which comprises:

(a) a steroid-sulfatase inhibitor; and


(b) an agent for hormone therapy and/or an agent for chemotherapy.

Claim 6 (canceled).


Claim 7 (currently amended): The therapeutic agent for a hormone-dependent cancer according to Claim 1, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, a compound represented by Formula (I), Formula (IA), or Formula (IB), or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R<sup>1</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or -NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R<sup>3</sup> and R<sup>4</sup> are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R<sup>2</sup> represents a monocyclic alcohol residue or a polycyclic alcohol residue],




(wherein -O-R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> have the same meanings as defined above, respectively), and




[wherein  $\text{R}^3$  and  $\text{R}^4$  have the same meanings as defined above, respectively;  $\text{R}^5$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group,  $-\text{NR}^6\text{R}^7$  (wherein  $\text{R}^6$  and  $\text{R}^7$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group),  $-\text{OR}^8$  (wherein  $\text{R}^8$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or  $-\text{SR}^{8\text{A}}$  (wherein  $\text{R}^{8\text{A}}$  has the same meaning as  $\text{R}^8$  defined above)].


Claim 8 (currently amended): The method for treating a hormone-dependent cancer according to Claim 2, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) described in Claim 7 or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R<sup>1</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or -NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R<sup>3</sup> and R<sup>4</sup> are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R<sup>2</sup> represents a monocyclic alcohol residue or a polycyclic alcohol residue].




(wherein  $-O-R^2$ ,  $R^3$ , and  $R^4$  have the same meanings as defined above, respectively), and




[wherein  $R^3$  and  $R^4$  have the same meanings as defined above, respectively;  $R^5$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group,  $-NR^6R^7$  (wherein  $R^6$  and  $R^7$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group),  $-OR^8$  (wherein  $R^8$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or  $-SR^{8A}$  (wherein  $R^{8A}$  has the same meaning as  $R^8$  defined above)].

Claim 9 (currently amended): The steroid-sulfatase inhibitor according to Claim 3, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) described in Claim 7 or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:




[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo;  $R^1$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or  $-NR^3R^4$  (wherein  $R^3$  and  $R^4$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or  $R^3$  and  $R^4$  are combined together with the adjacent nitrogen

atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R<sup>2</sup> represents a monocyclic alcohol residue or a polycyclic alcohol residue],




(wherein -O-R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> have the same meanings as defined above, respectively), and




[wherein R<sup>3</sup> and R<sup>4</sup> have the same meanings as defined above, respectively; R<sup>5</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, -NR<sup>6</sup>R<sup>7</sup> (wherein R<sup>6</sup> and R<sup>7</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), -OR<sup>8</sup> (wherein R<sup>8</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or -SR<sup>8A</sup> (wherein R<sup>8A</sup> has the same meaning as R<sup>8</sup> defined above)].


Claim 10 (currently amended): The kit for treating according to Claim 4, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) described in Claim 7 or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R<sup>1</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or -NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R<sup>3</sup> and R<sup>4</sup> are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R<sup>2</sup> represents a monocyclic alcohol residue or a polycyclic alcohol residue],




(wherein -O-R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> have the same meanings as defined above, respectively), and




[wherein R<sup>3</sup> and R<sup>4</sup> have the same meanings as defined above, respectively; R<sup>5</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, -NR<sup>6</sup>R<sup>7</sup> (wherein R<sup>6</sup> and R<sup>7</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), -OR<sup>8</sup> (wherein R<sup>8</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or -SR<sup>8A</sup> (wherein R<sup>8A</sup> has the same meaning as R<sup>8</sup> defined above)].


Claim 11 (currently amended): The pharmaceutical composition according to Claim 5, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) described in Claim 7 or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R<sup>1</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or -NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R<sup>3</sup> and R<sup>4</sup> are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R<sup>2</sup> represents a monocyclic alcohol residue or a polycyclic alcohol residue],



(wherein -O-R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> have the same meanings as defined above, respectively), and



[wherein  $R^3$  and  $R^4$  have the same meanings as defined above, respectively;  $R^5$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group,  $-NR^6R^7$  (wherein  $R^6$  and  $R^7$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group),  $-OR^8$  (wherein  $R^8$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or  $-SR^{8A}$  (wherein  $R^{8A}$  has the same meaning as  $R^8$  defined above)].

Claims 12-24 (canceled).

Claim 25 (currently amended): The therapeutic agent for a hormone-dependent cancer according to Claim 1, ~~7, 13, or 19~~, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a luteinizing hormone-releasing hormone (LH-RH) agonist.

Claim 26 (currently amended): The method for treating a hormone-dependent cancer according to Claim 2, ~~8, 14, or 20~~, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 27 (currently amended): The steroid-sulfatase inhibitor according to Claim 3, ~~9, 15, or 21~~, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 28 (currently amended): The kit for treating according to Claim 4, 10, 16, or 22, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 29 (currently amended): The pharmaceutical composition according to Claim 5, 11, 17, or 23, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 30 (canceled).

Claim 31 (currently amended): The therapeutic agent for a hormone-dependent cancer according to Claim 1, ~~7, 13, or 19~~, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 32 (currently amended): The method for treating a hormone-dependent cancer according to Claim 2, ~~8, 14, or 20~~, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 33 (currently amended): The steroid-sulfatase inhibitor according to Claim 3, ~~9, 15, or 21~~, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 34 (currently amended): The kit for treating according to Claim 4, ~~10, 16, or 22~~, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 35 (currently amended): The pharmaceutical composition according to Claim 5,~~11~~,  
~~17, or 23~~, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 36 (canceled).